Dendreon Will Likely Require Refinancing Before Re-Submitting Provenge BLA
This article was originally published in The Pink Sheet Daily
Executive Summary
Company believes it has the necessary cash to extend through timing of interim results of IMPACT study evaluating the cancer vaccine in 2008.
You may also be interested in...
Provenge Review In 2008 Hinges On IMPACT Interim Analysis
FDA will accept positive interim analysis of survival from the Phase III trial for registration of the therapeutic cancer vaccine, Dendreon confirms.
Provenge Review In 2008 Hinges On IMPACT Interim Analysis
FDA will accept positive interim analysis of survival from the Phase III trial for registration of the therapeutic cancer vaccine, Dendreon confirms.
Dendreon’s Therapeutic Vaccine Provenge Gets “Complete Response” From FDA
FDA is requesting additional clinical data to support the efficacy of Dendreon’s BLA.